Evidence Feed - LARVOL VERI

No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	obecabtagene autoleucel Sensitive: A1 - Approval FDA - 1 week (New A1) obecabtagene autoleucel Sensitive : A1 FDA - 1wk	obecabtagene autoleucel Sensitive: A1 - Approval FDA - 1 week obecabtagene autoleucel Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
CD20 positive	Chronic Lymphocytic Leukemia	CD20 positive	Chronic Lymphocytic Leukemia	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab-cmkb Sensitive: A1 - Approval margetuximab-cmkb Sensitive : A1	margetuximab-cmkb Sensitive: A1 - Approval margetuximab-cmkb Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1